Curis Lifesciences SME IPO Opens

1. Curis Lifesciences SME IPO Opens Curis Lifesciences, a pharmaceutical company specializing in contract manufacturing and product development, has launched its Rs 27.5 crore SME IPO for subscription from November 7 to November 11, 2025. This public issue marks a strategic step in the company’s expansion and operational growth plans. IPO Details The Curis Lifesciences SME IPO comprises a fresh issue of 21.5 lakh equity shares at a price band of Rs 120–128 per share, with a minimum investment size of Rs 2.56 lakh (2,000 shares per lot). The shares are proposed to be listed on the NSE SME platform on November 14, 2025. Before the issue opened, anchor investors subscribed Rs 7.81 crore, reflecting strong early confidence in the company’s business model and growth potential. About Curis Lifesciences Based in Gujarat, Curis Lifesciences operates in the pharmaceutical and life sciences sector, focusing on contract manufacturing, formulation development, and product innovation. The company serves over 100 corporate clients globally, offering solutions that meet international quality and regulatory standards. Its diversified business model enables it to cater to both domestic and international pharmaceutical markets, ensuring steady revenue streams and scalable growth. Financial Performance Curis Lifesciences has exhibited consistent financial progress in recent years. ● Revenue: Rs 49.6 crore, a 38% year-on-year growth ● Profit After Tax (PAT): Rs 6.1 crore, an increase of 25% over the previous year This robust financial performance highlights the company’s operational efficiency and expanding market footprint within India’s fast-growing pharma industry. Utilisation of IPO Proceeds The company aims to strategically deploy the Rs 27.5 crore raised from the IPO toward key objectives, including: ● Infrastructure expansion – Rs 6 crore, focused on facility upgrades and new storage capacities ● Loan repayment – Rs 1.9 crore ● Overseas product registration – Rs 2.7 crore

2. ● Working capital requirements – Rs 11.25 crore These investments are designed to strengthen Curis Lifesciences’ manufacturing capabilities and accelerate its entry into new global markets. Anchor Investment and Market Sentiment The participation of anchor investors to the tune of Rs 7.81 crore indicates institutional confidence in the Curis Lifesciences IPO. The company’s consistent revenue growth, coupled with a clear focus on R&D and global product approvals, positions it well within the SME pharma ecosystem. Industry and Market Outlook India’s pharmaceutical industry continues to grow at a rapid pace, driven by increasing healthcare awareness, global outsourcing, and innovation-led manufacturing. The SME IPO segment has gained momentum in 2025, with investors showing strong interest in small and mid-sized companies offering niche solutions and scalable business models. The Curis Lifesciences SME IPO aligns with this trend, giving investors a chance to participate in a fundamentally strong, innovation-driven pharmaceutical company. Conclusion With its proven financial performance, robust client base, and strategic use of IPO funds, Curis Lifesciences aims to strengthen its position in the Indian and global pharma landscape. For investors, the Curis Lifesciences SME IPO represents an opportunity to tap into the growing demand for high-quality pharmaceutical contract manufacturing and product development services.